2型糖尿病患者における治験薬（PF-07081532）およびリベルサスの効果、ならびに肥満患者におけるPF-07081532の効果を個別に評価する治験

基本情報

NCT ID

NCT05579977

ステータス

中止

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

902

治験依頼者名

Pfizer

概要

The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals with obesity without diabetes will be included in the study. Those participating in the diabetes part of the study, will receive either active study drug, placebo, or an approved treatment called Rybelsus. Those in the obesity part of the study, will receive either active study drug or placebo. The study will last for about 36 weeks except for the first 25% of the participants that enter in which case the study will last for approximately 48 weeks. during this time there will be visits every 4 weeks with phone calls in between.

対象疾患

介入

依頼者（Sponsor）

実施施設 (9)